What is Adalimumab-atto Subcutaneous
Adalimumab-atto subcutaneous injection is a medication used to treat various autoimmune diseases. It is a biosimilar to adalimumab, which is a medication used to treat rheumatoid arthritis, Crohn’s disease, and various other conditions. Adalimumab-atto is a monoclonal antibody that binds to tumor necrosis factor (TNF), a protein that plays a role in the immune response. By blocking TNF, adalimumab-atto reduces inflammation and prevents damage to the joints, intestines, and other organs.
Benefits of Adalimumab-atto Subcutaneous
and Its Uses.
adalimumab-atto subcutaneous is a medication used to treat autoimmune diseases, including Crohn’s disease, ulcerative colitis, and rheumatoid arthritis. It is a tumor necrosis factor blocker, which means it blocks the activity of tumor necrosis factor (TNF), a protein that plays a role in inflammation. by blocking TNF, adalimumab-atto subcutaneous can help reduce inflammation and pain.
adalimumab-atto subcutaneous is given as a subcutaneous injection, meaning it is injected under the skin. It is available as a prefilled syringe or a pen.
adalimumab-atto subcutaneous is used to treat a wide variety of autoimmune diseases, including:
Side Effects and Dosage of Adalimumab-atto Subcutaneous
Adalimumab-atto (Humira) is a recombinant human monoclonal antibody that is used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. It is a TNF-inhibitor that binds to tumor necrosis factor-alpha (TNF-alpha) to prevent it from causing inflammation. Adalimumab-atto is available as a subcutaneous injection.
The recommended dosage of adalimumab-atto is 40 mg injected subcutaneously every other week.
Common side effects of adalimumab-atto include:
-Upper respiratory tract infections
-Injection site reactions
Adalimumab-atto should not be used in pregnant women or women